'Mad Money' Lightning Round: VMware Is the One to Own

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


NEW YORK (TheStreet) -- Here's what Jim Cramer had to say about some of the stocks callers offered up during the Mad Money Lightning Round Thursday evening:

Celgene (CELG): "Right now this group is soft. When it goes to $140, you buy more."

Pharmacyclics (PCYC): "I still like this one. People don't want to own these right now, but hold onto it."

Bluebird Bio (BLUE): "This is a speculative biotech and those are going higher."

VMware (VMW): "This is the right one to own. They had a great quarter."

Facebook (FB): "These are coming down but I would hold onto it and buy more as it comes down."

FireEye (FEYE): "This is another high multiple tech stock. It's going to recharge then go higher."

To read a full recap of "Mad Money" on CNBC, click here.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

-- Written by Scott Rutt in Washington, D.C.

To email Scott about this article, click here: Scott Rutt

Follow Scott on Twitter @ScottRutt or get updates on Facebook, ScottRuttDC

More from Jim Cramer

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Using Technical Analysis to Profit: Cramer's 'Mad Money' Recap (Friday 5/18/18)

Using Technical Analysis to Profit: Cramer's 'Mad Money' Recap (Friday 5/18/18)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer Equates Investing to Blackjack -- and so the Market Becomes the House.

Cramer Equates Investing to Blackjack -- and so the Market Becomes the House.

Cramer's Team is Being Patient with the Financials -- Though They May Add More

Cramer's Team is Being Patient with the Financials -- Though They May Add More